Dihexa for ALS & Motor Neurone Disease (MND): HGF/c-Met Motor Neuron Protection — The 2026 UK Review

Five thousand families in the UK at any one time. Around 2,200 new motor neurone disease diagnoses each year and a similar number of deaths, with a median survival from symptom onset of just two to three years. May is ALS Awareness Month, and the field is more active in 2026 than at any point in the last decade — on 7 May 2026, the Longitude Prize on ALS announced Discovery Awards of £100,000 each to 20 international AI-driven drug-discovery teams, including the Sheffield-led Decode ALS consortium. The EXPERTS-ALS adaptive platform added neflamapimod in February and a Raya Therapeutic agent in March, with RT 1999 (Smilagenin) due to follow. The MND-SMART trial in Edinburgh and Sheffield continues recruitment on tacrolimus. Tofersen (Qalsody) is now an established option for the ~2% of MND patients with SOD1 mutations. The Relyvrio (AMX0035) story has reset expectations for unproven approaches. Through all of this, search interest in peptides for ALS, HGF for motor neurone disease and Dihexa for neuroprotection has risen sharply. The mechanistic case is more direct than for most indications — Engensis (VM202) is, after all, a plasmid HGF gene therapy that completed a Phase 2a safety study in ALS — but the human Dihexa evidence is zero. This is the rigorous 2026 UK review.

Motor Neurone Disease in the UK in 2026: 5,000 Patients, a Field Finally Moving

The headline numbers for motor neurone disease in the UK have not shifted much over the last decade, but the research landscape around them has. The MND Association estimates around 5,000 people are living with motor neurone disease at any one time, with approximately 2,200 new diagnoses each year and a similar number of deaths. The incidence is roughly 2 per 100,000 and the prevalence approximately 6 per 100,000 — figures broadly consistent with the 2023 global systematic review of ALS prevalence and incidence. Median survival from symptom onset is 2-3 years, although approximately 10% of patients survive more than a decade; rare slowly progressive presentations (primary lateral sclerosis, progressive muscular atrophy, some flail-arm or flail-leg variants) can extend further still.

UK epidemiology is documented in the Motor Neuron Disease Register for England, Wales and Northern Ireland (Opie-Martin et al., 2020), the first national MND register in the UK. The register confirms an age-of-onset peak in the seventh decade, a male-to-female ratio approaching 3:2 in younger-onset cases, a familial component in approximately 10% of cases (most commonly C9orf72 hexanucleotide repeat expansion, then SOD1, TARDBP/TDP-43 and FUS), and meaningful regional variation in time-to-diagnosis. The clinical phenotype divides into limb-onset (around 70%) and bulbar-onset (around 30%) presentations, with bulbar-onset disease carrying a shorter median survival.

MND is the umbrella UK term; in the United States the same condition is most commonly called amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease. Within MND the major subtypes are: ALS (combined upper and lower motor neuron involvement, ~85% of cases), progressive bulbar palsy (PBP, bulbar onset, ~10%), primary lateral sclerosis (PLS, upper motor neuron only, <5%), and progressive muscular atrophy (PMA, lower motor neuron only, ~5%). Spinal and bulbar muscular atrophy (SBMA, Kennedy's disease) is a separate X-linked neuromuscular condition with overlapping phenotypic features. ALS-frontotemporal dementia (ALS-FTD) is the high-cognitive-overlap end of the same TDP-43 spectrum, accounting for 10-15% of ALS clinical pictures.

What has changed in 2025-2026 is the breadth of the UK trial pipeline and the public-private funding architecture around it. The MND Association awarded £14.9 million in new research grants in 2025. The NIHR has committed £8 million to accelerate MND treatment research. The UK Dementia Research Institute hosts a substantial motor neurone disease programme. The Longitude Prize on ALS, launched in 2025 with a £7.5 million purse, completed its first Discovery Award stage on 7 May 2026.

What has not changed is the standard of care. NICE TA20 has recommended riluzole since 2001; the most recent NICE NG42 (Motor neurone disease: assessment and management) remains the active UK guideline, recommending multidisciplinary specialist clinic input (neurology, respiratory, gastroenterology, speech and language therapy, occupational therapy, physiotherapy, dietetics, neuropsychology, palliative care), non-invasive ventilation (NIV / NIPPV) for ventilatory failure, gastrostomy feeding (PEG / RIG) where bulbar dysfunction or weight loss is significant, and proactive symptom management for sialorrhoea, spasticity, cramps, emotional lability and pain. The NHS multidisciplinary clinic model is, by international standards, well organised, and is associated with improved survival independent of riluzole — though clinic geography is uneven and time-to-clinic-from-diagnosis varies. The clinical-trial pipeline, the multidisciplinary clinic and the patient community are the three structural assets that any pharmacological newcomer (Dihexa included) is competing alongside.

The Biology of Motor Neurone Disease: What's Actually Going Wrong

Before asking whether Dihexa could plausibly help, it is worth being precise about what motor neurone disease actually is at a cellular level. The clinical picture — muscle wasting, weakness, fasciculations, spasticity, bulbar dysfunction, eventual respiratory failure — arises from the loss of two anatomically distinct populations of neurons.

Upper and Lower Motor Neurons

Upper motor neurons (UMNs) are the pyramidal Betz cells in motor cortex layer V and their long descending axons in the corticospinal and corticobulbar tracts. Their loss produces the upper-motor-neuron clinical signs: spasticity, hyperreflexia, extensor plantar responses and (in the bulbar pathway) pseudobulbar palsy with emotional lability. Lower motor neurons (LMNs) are the alpha motor neurons in the anterior horn of the spinal cord and the cranial motor nuclei (predominantly hypoglossal, facial and trigeminal motor nuclei) and their axons projecting through peripheral nerves to muscle. Their loss produces lower-motor-neuron signs: muscle wasting, fasciculations, hyporeflexia, weakness and (in bulbar muscles) dysarthria, dysphagia and sialorrhoea. ALS is defined by the combination of UMN and LMN involvement; primary lateral sclerosis is pure UMN; progressive muscular atrophy is pure LMN; progressive bulbar palsy is bulbar-predominant.

The Histopathological Substrate: TDP-43 and the SOD1 Exception

Around 97% of ALS cases — including essentially all sporadic disease and most familial disease — share a common histopathological substrate: cytoplasmic aggregates of TAR DNA-binding protein 43 (TDP-43) in surviving motor neurons. The remaining ~3% have SOD1 aggregates (in SOD1 mutation carriers) or rarer FUS aggregates. TDP-43 is normally a nuclear RNA-binding protein; in ALS it mislocalises to the cytoplasm, undergoes hyperphosphorylation and ubiquitination, and forms insoluble aggregates that disrupt RNA metabolism, axonal transport and proteostasis. C9orf72-associated ALS (the most common genetic cause, accounting for around 40% of familial cases and 8% of sporadic cases) additionally shows characteristic dipeptide-repeat protein aggregates from the GGGGCC hexanucleotide repeat expansion.

This distinction matters for any HGF/c-Met-modulator argument. The earliest preclinical HGF-in-ALS data came from SOD1-G93A transgenic mice, which model the ~2% of ALS that is SOD1-driven. The 2023 Hayashi et al. paper in Gene Therapy took a substantial step further by demonstrating that AAV-vector-delivered HGF modulates neuroimmune signalling in the motor cortex in TDP-43 pathology, extending HGF biology to the dominant non-SOD1 ALS mechanism. This is what makes the HGF/c-Met system more interesting than most candidate ALS pathways: it has preclinical engagement across both SOD1 and TDP-43 disease.

Cell-Autonomous and Non-Cell-Autonomous Injury

Motor neuron death in ALS is not cell-autonomous. Astrocytes, microglia, oligodendrocytes and even skeletal muscle contribute. Astrocytes carrying ALS mutations are toxic to wild-type motor neurons in co-culture; ALS-mutant microglia exacerbate disease progression in transgenic mice; oligodendrocyte dysfunction precedes overt motor neuron loss. This non-cell-autonomous picture is why approaches that act on glia, neuroinflammation or neuromuscular junctions — including HGF, which has well-described actions on astrocytes, microglia and neuromuscular junction maintenance — have repeatedly shown larger effects in preclinical models than pure motor-neuron-targeted interventions.

One specific astrocytic mechanism is directly relevant: in ALS, astrocytic glutamate transporter EAAT2 (GLT-1 in rodents) is downregulated in spinal cord and motor cortex. This causes accumulation of synaptic glutamate and excitotoxic motor neuron injury. Riluzole is thought to work in part by attenuating glutamatergic release, providing its modest 2-3 month survival benefit. HGF has been shown to restore EAAT2/GLT-1 expression in ALS models — an excitotoxicity-protection mechanism that converges with riluzole on the same final pathway by a different route.

The Neuromuscular Junction

One of the earliest pathological events in ALS, well before symptom onset, is denervation at the neuromuscular junction (NMJ). The distal axon retracts from the muscle endplate, fasciculations appear, and surviving motor units enlarge by collateral sprouting to compensate. Eventually compensatory sprouting fails and clinical weakness emerges. This is the rationale for HGF delivery intramuscularly in the Engensis (VM202) programme: locally secreted HGF acts on motor nerve terminals to maintain the NMJ, support axonal regeneration, and recruit compensatory sprouting before clinical denervation. The biology is reasonable; the open question is whether the delivered HGF dose at the relevant nerve terminals is sufficient to alter the underlying disease trajectory in humans.

The HGF/c-Met System in Motor Neurone Disease: The Evidence in Detail

The HGF/c-Met argument for motor neuron protection is one of the strongest single biological cases in the ALS literature, with a body of preclinical work going back over two decades and one direct clinical translation already in the books. In our editorial judgement this is the single strongest mechanistic case Dihexa has for any neurodegenerative indication. The human Dihexa data, as always, remains zero — but the upstream biology is unusually well grounded.

HGF and c-Met in the Motor System

Hepatocyte growth factor (HGF) was first characterised as a hepatocyte mitogen, but the protein has paracrine and trophic actions across many tissues. In the nervous system, HGF acts through its tyrosine-kinase receptor c-Met (encoded by the MET proto-oncogene) to promote neuronal survival, axonal extension, dendritic branching, synaptic remodelling and glial homeostasis. c-Met is expressed on motor neurons, particularly during development and re-expressed after injury, and on the astrocytes, microglia and Schwann cells that surround motor neurons and their axons. The 2021 Frontiers review of HGF/MET in brain development and neurological disorders remains the best single overview of the pathway in CNS biology.

Sun et al. 2002: HGF Overexpression Retards ALS Progression in SOD1 Mice

The foundational HGF-in-ALS paper is Sun et al. (2002) in the Journal of Neuroscience. Sun and colleagues crossed SOD1-G93A transgenic mice (the standard ALS mouse model, expressing a mutant human SOD1 transgene that causes a familial form of human ALS) with transgenic mice over-expressing human HGF under a neuron-specific promoter. The double-transgenic mice (SOD1-G93A × HGF) showed: a marked attenuation of motor neuron loss in the spinal cord ventral horn; preservation of brainstem motor nuclei (facial, hypoglossal); reduced microgliosis and astrogliosis; restored astrocytic glutamate transporter EAAT2 expression; and a significant prolongation of life span. The effect size in this model was, for ALS pharmacology, very large.

Ishigaki et al. 2007: Intrathecal HGF Slows Disease in Rats

The next critical step was translational: could exogenous HGF, given after symptom onset (the realistic clinical scenario), modify disease in a non-transgenic-overexpression model? Ishigaki and colleagues (J Neuropathol Exp Neurol, 2007) used transgenic rats expressing human SOD1-H46R and delivered recombinant human HGF by continuous intrathecal infusion via implanted pump, starting at paralysis onset, for 4 weeks. Intrathecal HGF attenuated motor neuron degeneration in the lumbar spinal cord and prolonged disease duration by approximately 63% compared with vehicle. This is the key translational paper for any HGF-in-ALS argument: it shows that the pathway is therapeutically accessible at clinically realistic dose, timing and route in a non-transgenic-overexpression context.

Kadoyama et al. 2007: Brainstem Motor Nuclei and Bulbar Onset

Kadoyama et al. (Neurosci Res, 2007) extended the Sun et al. line of work to the brainstem motor nuclei specifically. In the SOD1-G93A × HGF mice, histological analyses showed a marked decrease in the number of microglia and reactive astrocytes and a significant attenuation of motor neuron loss in the facial and hypoglossal motor nuclei. These nuclei are the substrates of bulbar dysfunction in ALS — dysarthria, dysphagia, sialorrhoea — and bulbar-onset disease carries a worse prognosis. The Kadoyama paper makes the case that HGF biology engages bulbar disease biology, which is clinically the hardest phenotype to treat.

Hayashi et al. 2023: TDP-43, the Motor Cortex and AAV-HGF

The single most important recent paper for the HGF-in-ALS argument is Hayashi et al. (Gene Therapy, 2023). The authors used a novel recombinant adeno-associated virus (rAAV) vector to deliver HGF intrathecally in a TDP-43 ALS mouse model. The intervention demonstrated neuroimmune modulation in the ALS motor cortex with TDP-43 pathology, lower phosphorylated TDP-43 burden, attenuated microglial activation and reduced motor cortex neuronal loss. This is the single biggest extension of HGF-in-ALS biology since 2007: it moves the pathway argument out of the SOD1 niche (2% of ALS) and into the TDP-43 mainstream (97% of ALS), and it engages the motor cortex layer (relevant to the upper motor neuron disease in ALS, primary lateral sclerosis and ALS-FTD).

Mechanistic Summary: How HGF Could Plausibly Help

The convergent mechanisms across the preclinical HGF-in-ALS literature are: (i) direct anti-apoptotic motor-neuron survival signalling via PI3K/AKT and MAPK pathways; (ii) restoration of astrocytic glutamate transporter EAAT2/GLT-1 with consequent attenuation of glutamatergic excitotoxicity (the same final pathway riluzole engages); (iii) suppression of motor cortex and spinal cord microgliosis and astrogliosis; (iv) maintenance of neuromuscular junction architecture and support for axonal regeneration via collateral sprouting; (v) modulation of TDP-43 neuroimmune cortical signalling. The pathway has biological actions on neurons, glia and neuromuscular junctions simultaneously — consistent with the non-cell-autonomous nature of MND pathology.

This is the cleanest single mechanistic-fit case the site has reviewed across any neurological indication. If a peptide is going to engage the right biology for motor neurone disease at all, HGF/c-Met is the right target.

Engensis (VM202): The Direct HGF Clinical Translation

If HGF/c-Met is the right target, the obvious next question is what happens when HGF biology is actually delivered to ALS patients. The answer in 2026 is: it has been tried, with Engensis (VM202), and the Phase 2a safety result is in.

What Engensis Is

Engensis (international nonproprietary name: donaperminogene seltoplasmid; older trade name VM202) is a plasmid DNA gene therapy developed by Helixmith (formerly ViroMed) that encodes two isoforms of human hepatocyte growth factor. It is delivered by intramuscular injection. Transfected muscle cells then locally secrete HGF, which acts paracrinely on neighbouring motor nerve terminals, neuromuscular junctions and supporting Schwann cells. Engensis is in Phase 3 development for diabetic peripheral neuropathy as the lead indication, with parallel programmes in amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease. The diabetic peripheral neuropathy Phase 3 (VM202-DPN-III-1) is the largest single trial of an HGF biologic in any indication.

The ALS Phase 2a Trial

The Engensis ALS Phase 2a trial (NCT03061500) was a double-blind, placebo-controlled, multi-centre study at five sites (four US, one Korea). Eighteen subjects were randomised 2:1 to Engensis or placebo. Each subject received two cycles of intramuscular injections at two-week intervals across months 0, 2 and 4, with 64 mg of plasmid Engensis or placebo per dosing cycle, for a total of 192 mg of Engensis over four months. The primary endpoint was safety and tolerability; efficacy outcomes (ALSFRS-R, slow vital capacity, hand-held dynamometry) were exploratory. ALS News Today's coverage of the topline data reported that Engensis was safe and well tolerated; the exploratory efficacy analyses were uninterpretable at this sample size, as expected.

Helixmith's 2022 press release formally reported the Phase 2a topline. As of mid-2026, no Phase 2b efficacy trial in ALS has been reported. The diabetic peripheral neuropathy programme has taken precedence in the company's pipeline. This is a meaningful gap: the cleanest preclinical HGF translation in ALS has stalled at Phase 2a, not because of safety but because of commercial prioritisation. For a patient looking at the HGF/c-Met system in 2026, this matters: the direct biologic that should answer the human-translation question for the pathway has not been studied beyond a small safety cohort.

Where Engensis Leaves Dihexa

Engensis is a biologic that directly delivers the HGF gene to muscle. Dihexa is a small angiotensin-IV-derived hexapeptide that is hypothesised to allosterically potentiate endogenous HGF/c-Met signalling. They share a target pathway but not a regulatory class, not a manufacturing class, not a dose, and not a clinical-evidence base. A patient cannot infer Dihexa's clinical behaviour from Engensis's Phase 2a safety data — pharmacokinetics, blood-brain-barrier penetration, off-target receptors and effect-size potential all differ substantially between a gene therapy and a peptide. What Engensis does establish is that engaging the HGF/c-Met pathway in human ALS patients is at least feasible from a safety standpoint. The efficacy question remains open for any HGF-pathway therapeutic, biologic or peptide.

The closest peptide relative of Dihexa, fosgonimeton (ATH-1017) — the phosphate prodrug developed by Athira Pharma — was not advanced into MND trials. The fosgonimeton SHAPE Phase 2 trial in Parkinson's disease dementia and dementia with Lewy bodies reported in 2024 (signal positive, see the Parkinson's review), but Athira did not run a motor neuron disease arm. The HGF/c-Met-modulator peptide class therefore has no clinical-stage human MND data, which is a substantial gap to cross before anyone can reasonably claim peptide HGF modulation works in motor neuron disease.

BDNF, Synaptic Plasticity and the Motor Neuron

Brain-derived neurotrophic factor (BDNF) is the canonical motor-neuron neurotrophin. Recombinant BDNF was, in fact, one of the very first growth-factor therapeutics actually tested in ALS patients — in two large Phase 3 trials in the 1990s — and both failed. This history matters and should be confronted directly in any peptide-for-ALS argument that invokes the BDNF axis.

The 1990s BDNF Trials

Recombinant methionyl human BDNF was administered subcutaneously and intrathecally in two large Phase 3 ALS trials in the 1990s, with substantial financial backing and high expectations. Both trials failed to demonstrate a survival or functional benefit. The bath of preclinical motor-neuron-survival data did not translate. The failure is generally attributed to: poor blood-brain-barrier penetration of subcutaneous BDNF; short half-life and inadequate spinal cord exposure even with intrathecal delivery; possible TrkB receptor downregulation under sustained ligand exposure; and the heterogeneity of late-stage ALS pathology, which may be beyond the reach of any single trophic-factor pathway. The BDNF-in-ALS Phase 3 failure is the structural reason that subsequent growth-factor work has emphasised either gene-therapy delivery (sustained local expression) or small-molecule downstream modulation, rather than direct recombinant protein.

BDNF, Motor Cortex and Skeletal Muscle in 2026

Modern BDNF biology in MND is more nuanced. BDNF is expressed by upper motor neurons in motor cortex, by spinal motor neurons themselves, and by skeletal muscle. Activity-dependent BDNF release at the neuromuscular junction supports motor unit maintenance. Reduced muscle BDNF expression is documented in ALS and may contribute to NMJ denervation. Exercise — specifically structured aerobic and resistance training under physiotherapy supervision — raises circulating and tissue BDNF and is increasingly recognised as a beneficial intervention in mild-to-moderate MND, despite the long-standing clinical caution about over-exertion. The MND Association's exercise guidance reflects this shift.

The Dihexa vs BDNF review on this site examines the "10 million times more potent" claim, but the right framing for ALS specifically is more cautious: the recombinant BDNF Phase 3 trials have already failed once. Any peptide that invokes the BDNF axis as its rationale needs to confront the question of why a small-molecule potentiator would succeed where the actual ligand failed in well-powered Phase 3. The plausible answers all hinge on better blood-brain-barrier penetration, sustained downstream signalling rather than transient receptor activation, or convergence with HGF/c-Met biology that BDNF lacks. None of these answers has been demonstrated in human MND.

Synaptic Plasticity in the Motor Cortex

The motor cortex in ALS is not a passive bystander. It is the site of upper motor neuron loss, of TDP-43 pathology, and of cortical hyperexcitability that may actually drive lower motor neuron injury through a "dying-forward" mechanism. The cortical hyperexcitability hypothesis — supported by transcranial magnetic stimulation studies, biomarker work and imaging — argues that abnormal motor cortex excitability precedes and propagates to lower motor neuron loss. If true, this places motor cortex synaptic plasticity squarely in the relevant biology for MND. Dihexa's hypothesised mechanism — HGF/c-Met-mediated synaptic potentiation, dendritic-spine support and BDNF-axis amplification — engages the right cortex layer (the Hayashi 2023 AAV-HGF paper demonstrated motor cortex engagement specifically). Whether engagement equals therapeutic benefit in human ALS remains entirely untested.

Dihexa vs the NHS Standard of MND Care

Setting Dihexa beside standard NHS motor neurone disease care is the right honest comparison for any reader who arrived at this page hoping a peptide might help. The standard of care is modest in absolute terms — MND remains a devastating disease with no cure — but it has data, it is free at the point of use, and it operates inside an MDT structure with twenty years of audited delivery experience.

Riluzole: The 2-3 Month Survival Benefit

Riluzole has been licensed for ALS in the UK since the 1990s and recommended by NICE TA20 as a treatment for ALS-type MND. Pooled meta-analysis suggests an approximately 2-3 month median survival benefit, modestly better in earlier-stage disease, with no clear functional benefit on ALSFRS-R. It is typically dosed at 50 mg twice daily orally; an oral suspension and a sublingual formulation are available for patients with bulbar dysfunction. Side effects include nausea, mild liver enzyme elevation (requiring periodic monitoring) and asthenia. Riluzole is the standard NHS first-line, offered to most newly diagnosed UK MND patients. Its mechanism is partly through glutamatergic transmission modulation — the same final pathway HGF engages by a different route.

Tofersen (Qalsody): The SOD1 Antisense Oligonucleotide

Tofersen (Qalsody) is an intrathecal antisense oligonucleotide that lowers SOD1 mRNA and protein in patients with SOD1-associated ALS — approximately 2% of all ALS cases. It received accelerated FDA approval in 2023 based on the Phase 3 VALOR trial neurofilament light chain biomarker data, despite the trial missing its primary functional endpoint at 28 weeks. Extension data showed dramatic and sustained reductions in plasma neurofilament light chain and signals of functional benefit. The ongoing ATLAS trial is testing tofersen in pre-symptomatic SOD1 mutation carriers with elevated neurofilament — an early-treatment paradigm that may turn out to be the right one for any disease-modifying ALS therapy. Tofersen requires monthly intrathecal injection at a specialist centre and has been considered for NHS use in confirmed SOD1-ALS in 2025-2026.

Relyvrio (AMX0035): The Cautionary Tale

AMX0035 (sodium phenylbutyrate plus taurursodiol) is the clearest cautionary tale in modern ALS therapeutics. The Phase 2 CENTAUR trial signal was strong enough to drive accelerated FDA approval in 2022 (marketed as Relyvrio in the US and Albrioza in Canada). The confirmatory Phase 3 PHOENIX trial, reporting in March 2024, did not meet its primary or secondary endpoints. Amylyx voluntarily withdrew Relyvrio from the US market in October 2024, and the FDA formally withdrew approval in August 2025. The drug was never approved in the UK or by NICE. The Relyvrio story is the reference point for setting expectations around any unproven ALS therapeutic: a Phase 2 signal that did not survive Phase 3, despite immense patient demand and rapid initial regulatory acceptance. For an unstudied research peptide bought without supervision, the comparison goes one further: Dihexa has no Phase 2 in MND at all.

NurOwn (Debamestrocel): The Stem-Cell Story

NurOwn (debamestrocel, by BrainStorm Cell Therapeutics) is an autologous mesenchymal stem cell therapy modified to secrete neurotrophic factors (including BDNF, GDNF, VEGF, HGF) for intrathecal administration in ALS. The Phase 3 trial did not meet its primary endpoint. The ALS Association's position and the FDA Adcomm review have both been complicated by the gap between mechanistic plausibility and trial results. NurOwn's relevance to a Dihexa-in-MND discussion is that part of its hypothesised mechanism is paracrine HGF secretion by the engineered stem cells — one more strand of the HGF/c-Met argument that has been clinically tested and has not yet delivered a clear functional signal.

Multidisciplinary Specialist Care: The Underrated Intervention

Across all of the above, the single most consistently survival-modifying intervention in ALS is not a drug. It is access to a multidisciplinary specialist MND clinic. UK MND specialist clinics integrate neurology, respiratory (for NIV optimisation), gastroenterology (for PEG / RIG gastrostomy timing), speech and language therapy, dietetics, occupational therapy, physiotherapy, neuropsychology, palliative care and MND Association support coordination. Multiple observational studies show clinic-attendance association with improved survival independent of riluzole. NICE NG42 recommends this model and the MND Association maintains a directory of UK specialist clinics. Non-invasive ventilation (NIV / NIPPV) for ventilatory failure provides one of the largest single benefits in moderate-to-severe MND; gastrostomy feeding stabilises nutrition in bulbar-dysfunction patients. Both of these have far more evidence than any pharmacological adjunct currently in the pipeline, peptide or otherwise.

Where That Leaves Dihexa

Against this backdrop — riluzole with a 2-3 month survival signal, tofersen with an emerging biomarker case in SOD1, the cautionary Relyvrio withdrawal, a stalled NurOwn programme, and a multidisciplinary clinic model with twenty years of audited benefit — the case for unsupervised Dihexa in MND collapses. The mechanistic argument remains the strongest the site has reviewed for any neurodegenerative indication; the clinical argument is the weakest possible (zero human data). The space where Dihexa could even theoretically be defended is adjunct to standard NHS care in a patient who has already exhausted clinical-trial options and has discussed it with their MND specialist team — and even that defence is thin because no specialist team can responsibly comment on a peptide for which no controlled human data exist.

2026 News Context: Longitude Prize, EXPERTS-ALS, MND-SMART and Beyond

The motor neurone disease research landscape in May 2026 is genuinely the most active it has been in a generation. This section captures the news context any reader should have when thinking about MND therapeutics in 2026, peptide or otherwise.

The Longitude Prize on ALS: May 2026 Discovery Awards

On 7 May 2026 — four days before this article was published — the Longitude Prize on ALS announced its first Discovery Awards. Twenty international teams each received £100,000 for using artificial intelligence to identify and validate new ALS drug targets, selected from almost 100 entries to the global call issued in June 2025. The prize is delivered by Challenge Works (part of Nesta) and the MND Association in partnership with LifeArc and the Alan Davidson Foundation, with a total purse of £7.5 million through to a final £1 million prize in early 2031.

The UK-led Decode ALS consortium — co-led by Professor Johnathan Cooper-Knock and Professor Richard Mead of the Sheffield Institute for Translational Neuroscience (SITraN), with collaborators at Yale University, the Weizmann Institute of Science and Columbia University — was among the winning teams. The University of Sheffield's announcement describes the consortium's AI-driven approach to identifying druggable targets in TDP-43 biology. The progression structure is: 2026 — 20 Discovery Awards of £100,000; 2027 — 10 teams advance to £200,000 each; 2028 — 5 teams advance to £500,000 each; 2031 — one team receives the final £1 million for the strongest validated target.

EXPERTS-ALS: The UK Adaptive Platform

EXPERTS-ALS (EXPErimental medicine Route To Success in Amyotrophic Lateral Sclerosis) is the UK's flagship adaptive early-phase ALS trial platform, co-led by Professor Christopher McDermott (University of Sheffield) and Professor Martin Turner (University of Oxford) across 11 UK MND specialist centres. The first participant was recruited in November 2024. The platform is designed to continually rotate experimental agents in and out, with biomarker-based decisions to advance or terminate each arm.

Recent additions: February 2026 — CervoMed's neflamapimod (a p38 mitogen-activated protein kinase alpha inhibitor with positive signals in dementia with Lewy bodies and Alzheimer's tauopathy preclinical models) was selected for EXPERTS-ALS testing. March 2026 — Raya Therapeutic announced the name of its EXPERTS-ALS arm candidate. Expected end of 2026 — RT 1999 (Smilagenin) is expected to enter the platform, with preclinical evidence supporting motor-neurone-protective protein expression.

For UK readers with MND who are interested in cutting-edge therapeutics, EXPERTS-ALS is the right route. The platform is hosted at major UK MND specialist centres in Sheffield, Oxford, King's College London, UCLH, Edinburgh, Manchester, Liverpool, Birmingham, Bristol, Cambridge and Newcastle. Eligibility is best discussed at a routine MND clinic appointment.

MND-SMART: Tacrolimus and the Edinburgh-Sheffield Platform

MND-SMART (Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial) is the UK's first MND multi-arm adaptive trial, hosted at the Anne Rowling Regenerative Neurology Clinic (Edinburgh) and the University of Sheffield. The Edinburgh Clinical Trials Unit coordinates the platform. The first-stage results published in 2024 led to refinement of the platform structure. The trial is currently testing tacrolimus as one of its active arms, with a typical participant period of around 18 months and the option to continue beyond formal randomisation.

MIROCALS: The 2024 Low-Dose Interleukin-2 Signal

The MIROCALS trial (Modifying Immune Response and OutComes in Amyotrophic Lateral Sclerosis), reported by the University of Sheffield in 2024, tested low-dose subcutaneous interleukin-2 (ld-IL-2) in 304 ALS patients across UK and French centres. The trial did not meet its primary endpoint on the intent-to-treat population but showed signals of survival benefit in pre-specified biomarker subgroups (neurofilament-light-chain-high) and provided strong evidence for the regulatory T-cell mechanism in MND immunobiology. MIROCALS is the most important UK ALS Phase 3 trial of the recent era and shapes the field's view of neuroinflammation as a tractable ALS target.

2026 Genetics: The Utrecht 18,000-Genome MND Study

A major 2026 international MND genetics study led by Utrecht researchers, with UK collaboration including the King's College London and Sheffield groups, sequenced the largest combined cohort yet — almost 18,000 people with MND and over 200,000 controls — and identified new gene candidates including YKT6, HTR3C, GBGT1 and KNTC1. The MND Association's coverage sets out the implications for risk stratification, future drug targets and the C9orf72/SOD1/TARDBP/FUS landscape that has dominated ALS genetics for the last decade. The Utrecht study is the foundational data the Decode ALS Longitude Prize team and similar AI-driven consortia will mine over the next five years.

News Summary: What 2026 Means for an MND Patient

For an MND patient or family in 2026: the field is more active than at any point since the 1990s recombinant-trophic-factor era, the UK has a credible adaptive trial pipeline (EXPERTS-ALS, MND-SMART), one HGF-pathway biologic has reached Phase 2a safety (Engensis/VM202) without progressing to efficacy testing, the AI-driven drug-discovery era is now genuinely starting (Longitude Prize Discovery Awards just announced), the cautionary Relyvrio story has reset Phase 3 expectations across the field, and the multidisciplinary specialist clinic model remains the highest-value single intervention. None of this changes the answer about Dihexa: zero human data in MND, mechanistic case unusually strong, opportunity cost relative to trial participation real.

ALS-Frontotemporal Dementia: The Cognitive Overlap

Around 50% of ALS patients show measurable cognitive or behavioural change on detailed neuropsychological testing, and 10-15% meet diagnostic criteria for ALS-frontotemporal dementia (ALS-FTD). The cognitive component is one of the most under-recognised aspects of MND clinical care, and one of the most directly relevant to a synaptogenic-peptide hypothesis.

ALS-FTD shares its core histopathology with the rest of ALS: TDP-43 proteinopathy. The C9orf72 hexanucleotide repeat expansion is the single largest shared genetic cause — the same mutation can present as ALS, FTD or ALS-FTD in the same family. Behavioural-variant FTD predominates in the ALS-FTD population, with disinhibition, apathy, loss of empathy and executive dysfunction more common than the language-variant FTD phenotypes. The clinical implications are substantial: ALS-FTD shortens survival, complicates the decision-making capacity needed for advance care planning, and carries higher carer burden.

The HGF/c-Met-modulator argument has an unusually clean fit here: the Hayashi 2023 AAV-HGF paper documented motor cortex neuroimmune modulation in TDP-43 pathology, which overlaps with frontal cortex pathology in ALS-FTD. The site's broader synaptogenic-peptide framing for other dementia indications — reviewed in the MCI & brain aging, Alzheimer's research and Parkinson's disease articles — applies in principle. The human Dihexa evidence in any FTD population (behavioural, semantic, non-fluent or ALS-FTD) is zero. The closest clinical-stage relative, fosgonimeton, was studied in mixed Alzheimer's/PDD/DLB cohorts, not FTD.

For patients and families navigating ALS-FTD, the support architecture is split. The MND Association covers the motor-neurone side; Rare Dementia Support (UCL) and Dementia UK cover the cognitive-frontotemporal side. NHS specialist behaviour and cognition clinics in major academic centres (Cambridge, UCL Queen Square, King's, Edinburgh, Manchester) provide combined assessment.

Dihexa Safety Considerations Specific to Motor Neurone Disease

No published Dihexa safety data exist in any motor neurone disease population. The following considerations are mechanistic, not empirical, and should not be interpreted as a safety profile. They are reasons for additional clinical caution in this specific patient group.

Polypharmacy and Drug Interactions

MND patients are commonly on multiple concurrent medications: riluzole (CYP1A2 substrate, hepatotoxicity monitoring required); baclofen, tizanidine or diazepam for spasticity (CNS depression, falls risk); amitriptyline, hyoscine, glycopyrronium or atropine drops for sialorrhoea (anticholinergic burden); opioids and benzodiazepines for breathlessness, pain or insomnia (respiratory depression in an already-vulnerable patient); citalopram, sertraline or mirtazapine for depression and pseudobulbar affect; quinine, baclofen or magnesium for cramps; melatonin for sleep. Interactions between Dihexa and any of these are entirely uncharacterised. The angiotensin-IV scaffold from which Dihexa derives also has uncharacterised effects on autonomic and blood-pressure regulation, which matters in a patient on antihypertensives or in advanced disease with autonomic dysfunction.

Bulbar Dysfunction and Drug Absorption

Bulbar-onset and bulbar-affected MND patients have unpredictable swallowing function and frequently switch to sublingual, transdermal or PEG-administered medications. Dihexa is most commonly self-administered orally or sublingually. Pharmacokinetics in bulbar dysfunction are entirely uncharacterised. Anyone with bulbar symptoms exploring Dihexa, against clinical advice, faces additional unpredictability of dose absorption.

The c-Met Cancer Question

c-Met is the proto-oncogene MET. Inappropriate c-Met activation contributes to several solid tumours including non-small-cell lung cancer (often via MET exon 14 skipping or MET amplification), gastric cancer, colorectal cancer, hepatocellular carcinoma, breast cancer and renal cell carcinoma. The cancer-risk question for any HGF/c-Met-modulating peptide applies across every Dihexa indication and is reviewed in more detail in the side effects and risks and chemo brain articles. In MND, the absolute lifetime cancer-recurrence risk is somewhat overshadowed by the much shorter disease-specific prognosis, but it is not zero, and survivors of comorbid malignancies, smokers, those with strong family histories or those with active surveillance for early-stage cancer warrant particular attention to this signal. The diabetic peripheral neuropathy Phase 3 of the closely related Engensis biologic provides a substantial human safety dataset on direct HGF gene delivery, but does not address potentiator-peptide pharmacology and was not powered for long-term cancer outcomes.

Research-Chemical Quality Control

Dihexa sold via the unregulated research-chemical market is not subject to MHRA-equivalent good-manufacturing-practice (GMP) quality control. Identity, purity, endotoxin levels, residual solvents and microbial contamination are not assured. For an immune-compromised, frail or advanced-disease patient — which most MND patients become — this is a non-trivial additional risk. The legitimate research peptide synthesis houses that supply academic laboratories operate to higher standards than the consumer-facing nootropic market, but the consumer-facing market is what most patients encounter.

The Opportunity Cost

The single most important safety concern is not pharmacological. It is opportunity cost. Time spent sourcing, dosing, monitoring and titrating an unstudied research peptide is time not spent on MND specialist clinic engagement, NIV optimisation, nutritional support, riluzole adherence, tofersen eligibility assessment for SOD1-mutation carriers, or clinical-trial enrolment through EXPERTS-ALS or MND-SMART. Every one of those alternatives has data; Dihexa does not. The disease trajectory in MND is fast and uncompromising. Misallocated time has a higher cost in MND than in almost any other neurological indication the site has reviewed.

An Evidence-Based 2026 Plan for an MND Patient

If you are an MND patient or family member who arrived at this page hoping for a peptide that could help, the honest answer is: it isn't Dihexa, and it isn't any unstudied research compound. What is genuinely available, evidence-based and free at the point of NHS use, in approximate order of priority, is:

1. MND specialist multidisciplinary clinic engagement. If not already enrolled, request referral to the nearest UK MND specialist clinic via your GP or neurologist. The MND Association maintains a UK directory. Clinic attendance is associated with survival benefit independent of pharmacotherapy.
2. Riluzole. Standard NHS first-line, recommended by NICE TA20. Start as soon as diagnosis is confirmed.
3. Tofersen (Qalsody) eligibility for SOD1 mutation carriers. Around 2% of MND patients carry SOD1 mutations. Genetic testing through MND specialist clinics is increasingly routine in 2026 and identifies the small but important subset for whom an actually disease-modifying ASO is plausibly accessible.
4. Clinical-trial enrolment. EXPERTS-ALS at 11 UK MND centres; MND-SMART at Edinburgh and Sheffield; the broader NIHR Be Part of Research portal. Trial participation provides supervised experimental therapy with safety monitoring and contributes data that helps every other MND patient.
5. Non-invasive ventilation (NIV / NIPPV). One of the largest single survival and quality-of-life interventions in moderate-to-severe MND. NICE NG42 recommends proactive respiratory monitoring and early NIV consideration.
6. Gastrostomy (PEG / RIG) for bulbar dysfunction. Stabilises nutrition; timing should be early when respiratory function is still adequate to tolerate the procedure.
7. Structured exercise under physiotherapy supervision. The old MND advice that all exercise was harmful has been substantially revised. Moderate aerobic and resistance training under specialist physiotherapy is associated with maintained function and possibly trophic-factor signalling benefit.
8. Symptom management and palliative care input. Sialorrhoea, spasticity, cramps, pseudobulbar affect, breathlessness, pain, anxiety and sleep are all treatable. Early palliative care involvement is associated with better quality of life and is no longer end-of-life-only.
9. MND Association support services. Equipment loan, financial-and-benefits navigation, regional support workers, the MND Association Helpline (0808 802 6262), local branches.
10. Carer support. Carers UK, MND Association carer services, and (for emotional support) the Samaritans on 116 123.

Dihexa, if it is to feature at all, is the very last item on this list, behind every evidence-based option, and only after explicit discussion with your MND specialist team — who will, in our judgement, decline to endorse it because there is no human data to comment on. That refusal is not paternalism; it is the right answer to a question that has not been studied.

The Bottom Line

The mechanistic case for an HGF/c-Met-modulating peptide in motor neurone disease is the cleanest single biological argument the site has reviewed across any neurological indication. HGF/c-Met is one of the best-validated motor-neuron-survival pathways in two decades of ALS preclinical literature. Sun 2002, Ishigaki 2007, Kadoyama 2007 and Hayashi 2023 collectively establish HGF biology across SOD1, TDP-43, motor cortex, brainstem and spinal cord motor nuclei. One direct HGF-pathway therapeutic (Engensis / VM202) has completed a Phase 2a safety study in ALS. The preclinical-to-clinical bridge for HGF in MND is meaningfully more advanced than for most candidate pathways.

The human evidence for Dihexa specifically in motor neurone disease is zero. No registered or completed clinical trial of Dihexa in any MND subtype. The closest clinical-stage peptide relative (fosgonimeton, ATH-1017) was not advanced into MND trials. The HGF-pathway translation that has reached patients (Engensis) is a biologic, not a peptide, and its efficacy in ALS is undetermined. The Relyvrio story is the right reference point for setting expectations around unproven approaches: a strong Phase 2 signal that did not survive Phase 3 confirmation. Dihexa does not have a Phase 2 in MND at all.

The clinically validated, NICE-recommended, NHS-delivered MND pathway is modest in absolute terms but real: multidisciplinary specialist clinic, riluzole, tofersen for the SOD1 minority, NIV, gastrostomy, structured exercise, palliative-care integration, MND Association support. Clinical-trial participation through EXPERTS-ALS and MND-SMART is the credible route to anything beyond standard care. May 2026 is, despite everything, the most hopeful single month for ALS research in many years, with the Longitude Prize Discovery Awards just announced and a UK trial pipeline more active than at any point since the 1990s.

Our honest 2026 answer is: standard NHS multidisciplinary MND care first, clinical-trial participation second, unlicensed peptides last — if at all, and not without explicit specialist clinical discussion. The HGF/c-Met pathway is the right biology. Dihexa is the wrong end of it for a patient making a real decision in 2026.

FAQ — Dihexa, HGF/c-Met and Motor Neurone Disease

Related Reading on Dihexa.co.uk

• Dihexa for Stroke Recovery & PSCI — the closest neurorepair indication with shared HGF/c-Met biology and post-stroke synaptic reorganisation.
• Dihexa for Multiple Sclerosis (MS) — the other major HGF-pathway neuro-immunological indication, with the Bai 2012 remyelination axis.
• Dihexa for Parkinson's Disease — the fellow neurodegenerative indication with the SHAPE PDD/DLB fosgonimeton cognitive signal.
• Dihexa for TBI, Concussion & Stroke Recovery — the neurorepair indication that shares the synaptic-rebuilding rationale with ALS at the cellular level.
• Dihexa for MCI & Brain Aging — the synaptic-loss case directly relevant to ALS-FTD cognitive overlap.
• Dihexa & Alzheimer's Research — the academic origin story and the TDP-43-positive Alzheimer subgroup that overlaps with ALS biology.
• Dihexa for Chemo Brain (CICI) — another indication where the c-Met cancer-risk question is directly relevant.
• Dihexa vs BDNF — the central potency claim, with the recombinant BDNF Phase 3 ALS failure as the right historical reference.
• Dihexa for Depression & Mood — relevant to MND-associated depression and pseudobulbar affect.
• Dihexa for Anxiety & Chronic Stress — relevant to MND-associated anxiety in patients and carers.
• Dihexa, Sleep & Memory Consolidation — ALS sleep architecture and the vivid-dream phenomenon.
• Dihexa for Long COVID Brain Fog — another neuroinflammation indication.
• Fosgonimeton & Athira — the closest clinical-stage HGF/c-Met-modulator relative and why it was not advanced into MND trials.
• Dihexa Review 2026 — effects timeline, oral vs sublingual, cycling protocols.
• Dihexa Stacking Guide — why combining Dihexa with riluzole or other MND medications needs prescriber oversight.
• Dihexa for Cognitive Enhancement — the broader cognition conversation.
• Mechanism of Action — HGF/c-Met, PI3K/AKT, dendritic spines.
• Benefits Overview — the broader claimed-benefit landscape, evidence-rated.
• Dosage Guide — community dose ranges and considerations.
• Side Effects & Risks — the general safety picture, including the c-Met cancer-risk conversation directly relevant to MND.
• UK Legal Status — where Dihexa sits in UK law and MHRA advertising rules.
• Research & Studies — the human and animal evidence base reviewed.
• Dihexa vs Other Nootropics — how Dihexa compares with Semax, Selank, Noopept, BPC-157, cerebrolysin and citicoline.
• Glossary — technical terms used on this page.
• Full Site FAQ — the broader question set across the site.

External Authoritative Sources Cited

• MND Association — UK national MND charity (helpline 0808 802 6262).
• MND Association — What is motor neurone disease? UK epidemiology and clinical overview.
• MND Association — Latest research news.
• EXPERTS-ALS trial — MND Association trial overview.
• University of Sheffield Clinical Research — Groundbreaking EXPERTS-ALS study for MND treatments.
• MND-SMART trial — clinical trial site.
• Edinburgh Clinical Trials Unit — MND-SMART.
• Anne Rowling Regenerative Neurology Clinic — MND-SMART.
• MND Scotland — Scottish national MND charity.
• International Alliance of ALS/MND Associations.
• International Alliance — Global Day Calendar (World ALS/MND Day).
• Longitude Prize on ALS — official site.
• University of Sheffield — The race to 'Decode ALS': Sheffield scientists awarded global prize for breakthrough AI drug discovery (May 2026).
• University of Sheffield — Landmark MIROCALS clinical trial provides new insight into treatment of MND.
• University of Sheffield — A turning point for the treatment of motor neurone disease.
• NICE NG42 — Motor neurone disease: assessment and management.
• NICE TA20 — Riluzole for the treatment of motor neurone disease.
• NHS — Motor neurone disease overview.
• NIHR — £8m to speed up research into new treatments for Motor Neurone Disease.
• UK Dementia Research Institute — Motor neuron disease research programme.
• UK MND Research Institute.
• NIHR Be Part of Research portal.
• Sun W et al. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS (J Neurosci, 2002).
• Ishigaki A et al. Intrathecal delivery of HGF from ALS onset suppresses disease progression in rat ALS model (J Neuropathol Exp Neurol, 2007).
• Kadoyama K et al. HGF attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS (Neurosci Res, 2007).
• Hayashi Y et al. Novel rAAV vector mediated intrathecal HGF delivery has an impact on neuroimmune modulation in the ALS motor cortex with TDP-43 pathology (Gene Therapy, 2023).
• Desai BS et al. HGF and MET: From Brain Development to Neurological Disorders (Frontiers Cell Dev Biol, 2021).
• ALS News Today — Engensis gene therapy for ALS found safe in small Phase 2a trial.
• Helixmith — Phase 2a topline results press release for Engensis (VM202) in ALS.
• VM202 / Engensis — Phase 3 in diabetic peripheral neuropathy (PMC review).
• ALS News Today — VM202/Engensis programme overview.
• ALZFORUM — Engensis therapeutic profile.
• Miller TM et al. Tofersen for SOD1 ALS (VALOR trial), N Engl J Med 2022.
• Tofersen orphan-drug regulatory update (PMC).
• Amylyx — formal intention to remove Relyvrio / Albrioza from the market.
• Federal Register — Withdrawal of Approval of New Drug Application for RELYVRIO (August 2025).
• ALS Association — Position on NurOwn (debamestrocel).
• Opie-Martin S et al. Motor Neuron Disease Register for England, Wales and Northern Ireland (Amyotroph Lateral Scler Frontotemporal Degener, 2020).
• Global Prevalence and Incidence of Amyotrophic Lateral Sclerosis: A Systematic Review (PMC, 2023).
• Vasta R et al. ALS Prevalence Projection in 2040 (Ann Clin Transl Neurol, 2026).
• New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022 (Frontiers in Pharmacology).
• Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective (PMC).
• ClinicalMetric — ALS Clinical Trials 2026 overview.
• University of Birmingham — Safety results pave way to next-stage trials for new MND drug.
• Wright JW & Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases (Neuroscience, 2015).
• Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the HGF/c-Met system (J Pharmacol Exp Ther, 2014).